FDA Safety Thresholds
IEC 60601-2-62
Mechanical Index (MI)
1.49
✓ Compliant (< 1.90)
ISPTA (Spatial-Peak Temp-Avg)
1.62 W/cm²
✓ Safe Non-Thermal
Estimated Tissue ΔT
+0.14 °C
✓ No Thermal Damage
Cavitation Risk
Low (0.08)
✓ Microbubble Stable
Mesolimbic Dopamine Circuit Response
Intervention Mode Contrast
| Dimension | Invasive DBS | Non-Invasive LIFU |
|---|---|---|
| Invasiveness | Craniotomy & Lead Implant | Intact Skull Ultrasound |
| Surgical Hemorrhage Risk | 1.5 – 3.0% | 0.0% (Non-invasive) |
| Spatial Precision | 1.0 mm (Electrode tip) | 1.5 – 3.0 mm (Focal waist) |
| Reversibility & Repetitions | Indwelling hardware | Flexible outpatient sessions |
Target Anatomical Co-Registration & Stereotaxic Coordinates
Medial-Lateral (X)
±7.5 mm
Anterior-Posterior (Y)
+12.0 mm
Dorsal-Ventral (Z)
-6.2 mm
Low-intensity focused ultrasound (LIFU) delivers pulsed acoustic pressure waves trans-cranially into subcortical structures. In refractory methamphetamine and opioid use disorders, hyperactive glutamatergic/dopaminergic projections from the nucleus accumbens shell and ventral striatum are modulated via mechanosensitive ion channel gating (Piezo1/TRP/TREK), suppressing compulsive craving behaviors without destructive tissue lesioning.
Acoustic Protocol Log & Safety Verification
[00:00] Initialized LIFU phased-array trans-skull acoustic engine.
[00:00] Target: Nucleus Accumbens (Bilateral).
[00:00] Mechanical Index (MI): 1.49 (Within FDA limit <1.9).
[00:00] Ready for clinical simulation run.